<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03547232</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-1413</org_study_id>
    <nct_id>NCT03547232</nct_id>
  </id_info>
  <brief_title>A Trial of Indomethacin in Acute Pancreatitis</brief_title>
  <official_title>A Randomized Controlled Trial of Indomethacin in Acute Pancreatitis- Effectiveness and Safety</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute pancreatitis (AP) is an inflammatory condition of the pancreas following the activated
      pancreatic enzymes induced by varied causes, with or without other organ(s) dysfunction. The
      production and release of inflammatory factors is generally considered as the key factor of
      pathogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly applied
      agents for inflammatory diseases. A series studies have proved that indomethacin can reduce
      the risk of post-endoscopic retrograde cholangiopancreatography (ERCP), but high-quality
      evidence is still lacking in the field of effectiveness of NSAIDs to treat, rather than
      prevent, other types of AP. Majority of animal experiments showed that NSAIDs had protective
      effects for organ functions, but the results of several preliminary clinical studies were
      inconsistent. Randomized controlled trials are eagerly awaited to elucidate its effects on
      AP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurence rate of organ dysfunction</measure>
    <time_frame>1 week</time_frame>
    <description>Accumulation of varied organ dysfunction, especially the cardiovascular, renal and respiratory systems</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurence rate of pancreatic necrosis</measure>
    <time_frame>1 month</time_frame>
    <description>Accumulation of the key local complication of acute pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of ICU admission</measure>
    <time_frame>1 month</time_frame>
    <description>Evaluation of critical severe acute pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 month</time_frame>
    <description>The number of deaths during a particular period of time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hospitalization cost</measure>
    <time_frame>1 month</time_frame>
    <description>Expense of acute pancreatitis</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Acute Pancreatitis</condition>
  <condition>Complication</condition>
  <arm_group>
    <arm_group_label>Indomethacin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Indomethacin SR 50mg q12h from day1 to day 7 plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Similar shape and size suppositories without indomethacin (Placebos) given q12h from admission day 1 to day 7, plus standard treatment for acute pancreatitis including adequate intravenous fluids, analgesics and early enteral nutrition support if possible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin SR</intervention_name>
    <description>Indomethacin SR 50mg given q12h from admission day 1 to day 7</description>
    <arm_group_label>Indomethacin group</arm_group_label>
    <other_name>YINDUOMEIXIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7</description>
    <arm_group_label>Standard group</arm_group_label>
    <other_name>sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients ages 18-75 years admitted to Peking Union Medical College Hospital
             (PUMCH) with a diagnosis of AP based on at least 2 of the following criteria:

          -  Abdominal pain characteristic of AP

          -  Serum amylase and/or lipase ≥ 3 times the upper limit of normal

          -  Characteristic findings of AP on abdominal CT scan will be screened for study
             enrollment.

        Exclusion Criteria:

          -  Onset time &gt;48 hours

          -  Presence of renal dysfunction (serum creatinine &gt; 1.5 *normal upper limit)

          -  Active peptic ulcer disease or GI bleeding

          -  Pregnancy or breast-feeding

          -  Use of daily antiplatelet or anticoagulant drug(s) within 2 week of presentation

          -  Hypersensitivity to NSAIDs

          -  New-onset, exacerbation or uncontrolled hypertension

          -  Presence of serious cardiovascular events, including severe heart failure, myocardial
             infarction (MI) and stroke

          -  Mental disability
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Wu, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong Wu, M.D.</last_name>
    <phone>8618612671010</phone>
    <email>dongwu@pumc.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Wu, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/?term=25872171</url>
    <description>A small sample study of NSAIDs for treatment of acute pancreatitis</description>
  </link>
  <results_reference>
    <citation>Gorsky VA, Agapov MA, Khoreva MV, Leonenko IV. The effect of lornoxicam on TLR2 and TLR4 messenger RNA expression and tumor necrosis factor-α, interleukin-6, and interleukin-8 secretion in patients with systemic complications of acute pancreatitis. Pancreas. 2015 Jul;44(5):824-30. doi: 10.1097/MPA.0000000000000344.</citation>
    <PMID>25872171</PMID>
  </results_reference>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>December 12, 2018</last_update_submitted>
  <last_update_submitted_qc>December 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>DONG WU</investigator_full_name>
    <investigator_title>Associate Professor of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Acute pancreatitis</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Organ dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

